8-K: CytoSorbents Appoints Peter J. Mariani as New CFO, Kathleen P. Bloch Retires

CytoSorbents Corporation has appointed Peter J. Mariani as its new Chief Financial Officer, effective August 14, 2024, while current CFO Kathleen P. Bloch retires and transitions to a consulting role.

Summary

• CytoSorbents Corporation announced the appointment of Peter J. Mariani as its new Chief Financial Officer, effective August 14, 2024.
• The current CFO, Kathleen P. Bloch, has retired from her position and will transition into a consulting role with the company to assist with the transition.
• Mr. Mariani's employment agreement includes an initial term ending December 31, 2025, with automatic one-year renewals unless either party provides 60 days' notice.
• He will receive an annual base salary of $425,000 and is eligible for an annual cash bonus of up to 45% of his base salary, contingent on performance and achievement of management milestones.
• Mr. Mariani will also be eligible for annual equity awards starting in 2025.
• As an inducement, Mr. Mariani received 80,000 time-based stock options, 215,000 performance-based stock options, 65,000 restricted stock units vesting over two years, 175,000 change-in-control restricted stock units, and 110,000 restricted stock units vesting on a change of control or after four years.
• Ms. Bloch's consulting agreement will remain in effect until December 31, 2025, and she will be compensated at an hourly rate of $335.
• She will also receive continued vesting of her previously awarded restricted stock units and reimbursement for health insurance costs under COBRA for 12 months.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the appointment of an experienced CFO and a smooth transition plan. The company's forward-looking statements are also optimistic, suggesting confidence in future growth.

Positives

• The appointment of Peter J. Mariani brings a seasoned financial leader with over 25 years of experience in high-growth medical device companies.
• Mr. Mariani's experience includes successful tenures at Axogen, Lensar, Hansen Medical, and Guidant Corporation.
• His track record includes growing Axogen's annual revenue from $27 million to nearly $160 million and raising approximately $250 million in capital.
• The transition plan includes Ms. Bloch serving as a consultant to ensure a smooth handover, leveraging her 11 years of experience with the company.
• The inducement awards for Mr. Mariani are designed to align his interests with the company's long-term success.

Negatives

• The retirement of Kathleen P. Bloch, while planned, represents a loss of institutional knowledge and experience.
• The company will incur additional costs associated with Ms. Bloch's consulting fees and COBRA health insurance reimbursements.
• The performance-based stock options for Mr. Mariani are contingent on achieving specific milestones by December 31, 2025, which introduces some uncertainty.

Risks

• The successful transition of CFO responsibilities from Ms. Bloch to Mr. Mariani is critical for maintaining financial stability and strategic direction.
• The company's ability to achieve the performance milestones required for Mr. Mariani's performance-based stock options is subject to market conditions and operational execution.
• There is a risk that the company may not be able to retain Mr. Mariani beyond the initial term of his employment agreement.
• The company's future growth and success are dependent on the successful commercialization of DrugSorb-ATR and continued growth of CytoSorb.

Future Outlook

The company anticipates rapid growth and believes Mr. Mariani's experience will be vital to their success, particularly with the potential marketing approval of DrugSorb-ATR in the U.S. and Canada and the continued growth of their OUS business with CytoSorb.

Management Comments

• Dr. Chan stated, 'Pete is a seasoned and accomplished medical device CFO whose many successes at high growth publicly-traded companies such as Axogen, Hansen Medical, and Guidant Corporation, speak for themselves.'
• Dr. Chan also said, 'We are thrilled to have Pete join CytoSorbents and be a key member of the management team.'
• Mr. Mariani stated, 'I am excited to join CytoSorbents during this pivotal time in the Company’s history.'
• Dr. Chan concluded, 'As we welcome Pete to CytoSorbents, we remain indebted to Kathy Bloch for her more than 11 years of dedication and leadership at the Company as a trusted colleague and friend...'

Industry Context

This announcement reflects a strategic move by CytoSorbents to strengthen its financial leadership as it prepares for potential regulatory approvals and further commercial expansion. The appointment of a CFO with a proven track record in high-growth medical device companies aligns with the company's ambitions to scale its operations and capitalize on market opportunities.

Comparison to Industry Standards

• The hiring of Peter J. Mariani, who previously served as CFO at Axogen, a company that grew annual revenue from $27 million to nearly $160 million, indicates CytoSorbents is aiming for similar rapid growth.
• The compensation package for Mr. Mariani, including a base salary of $425,000 and potential bonuses, is competitive with industry standards for CFOs at publicly traded medical device companies.
• The use of inducement awards, including stock options and restricted stock units, is a common practice to attract and retain top executive talent in the biotech and medical device sectors.
• The transition of Kathleen P. Bloch to a consulting role is a standard practice to ensure continuity and knowledge transfer during executive changes, similar to transitions seen at other companies.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced CFO positively, potentially increasing investor confidence.
• Employees may experience a change in leadership within the finance department.
• Customers and partners may not be directly impacted by this change, but the company's financial stability and growth prospects could indirectly affect them.
• The smooth transition of the CFO role is intended to minimize any disruption to the company's operations.

Next Steps

• Peter J. Mariani will assume his role as CFO on August 14, 2024.
• Kathleen P. Bloch will transition to her consulting role to assist with the CFO transition.
• The company will work towards achieving the milestones required for Mr. Mariani's performance-based stock options.
• CytoSorbents will continue to pursue regulatory approvals for DrugSorb-ATR in the U.S. and Canada.

Key Dates

Keywords

Chief Financial Officer, CFO, Peter J. Mariani, Kathleen P. Bloch, executive appointment, retirement, consulting agreement, stock options, restricted stock units, inducement awards, medical device, financial management, CytoSorbents